内容

目次

Section 1: General aspects of vaccination 1. A short history of vaccination 2. Vaccine immunology 3. Correlates of protection 4. The vaccine industry 5. Vaccine manufacturing 6. Evolution of adjuvants across the centuries 7. Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States 8. Passive immunization 9. General immunization practices Section 2: Licensed Vaccines and Vaccines in Development 10. Adenovirus vaccines 11. Anthrax vaccines 12. Biodefense and special pathogen vaccines 13. Cancer vaccines 14. Cholera vaccines 15. Combination vaccines 16. Cytomegalovirus vaccines 17. Dengue vaccines 18. Diarrhea caused by bacteria 19. Diphtheria toxoid 20. Ebola vaccines 21. Enterovirus 71 22. Epstein-Barr virus vaccines 23. Haemophilus influenzae type b vaccines 24. Hepatitis A vaccines 25. Hepatitis B vaccines 26. Hepatitis C vaccines 27. Hepatitis E vaccines 28. Herpes simplex virus vaccines 29. Human immunodeficiency virus vaccines 30. Human papillomavirus vaccines 31. Inactivated influenza vaccines 32. Influenza vaccine-live 33. Japanese encephalitis vaccines 34. Lyme disease vaccines 35. Malaria vaccines 36. Maternal immunization 37. Measles vaccine 38. Meningococcal Capsular A, C, W, and Y Conjugate Vaccines 39. Mumps vaccines 40. Noninfectious disease vaccines 41. Norovirus 42. Parasitic disease vaccines 43. Pertussis vaccines 44. Plague vaccines 45. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 46. Pneumococcal polysaccharide vaccines 47. Poliovirus vaccine-inactivated 48. Poliovirus vaccine-live 49. Rabies vaccines 50. Respiratory syncytial virus vaccines 51. Rotavirus vaccines 52. Rubella vaccine 53. Smallpox and vaccinia 54. Staphylococcus aureus vaccines 55. Streptococcus group A vaccines 56. Streptococcus group B vaccines 57. Tetanus toxoid 58. Tick-borne encephalitis virus vaccines 59. Tuberculosis vaccines 60. Typhoid fever vaccines 61. Varicella vaccine 62. Yellow fever vaccine 63. Zoster vaccine Section 3: New Technologies 64. Technologies for making new vaccines 65. The development of gene-based vectors for immunization 66. Technologies to Improve Immunization Section 4: Vaccination of special groups 67. Vaccination of immunocompromised hosts 68. Vaccination of human immunodeficiency virus-infected persons 69. Vaccines for international travel 70. Vaccines for health care personnel Section 5: Public health and regulatory issues 71. Immunization in the United States 72. Immunization in Europe 73. Immunization in the Asia-Pacific region 74. Immunization in developing countries 75. Community Protection 76. Economic analyses of vaccine policies 77. Regulation and testing of vaccines 78. Regulation of vaccines in Europe 79. Regulation of vaccines in low and middle-income countries 80. Vaccine safety 81. Legal issues 82. Ethics Appendix Websites and Applications for Mobile Devices with Information about Immunization